

Title (en)
COMBINATION THERAPY WITH NEOANTIGEN VACCINE

Title (de)
KOMBINATIONSTHERAPIE MIT NEOANTIGEN-IMPFSTOFF

Title (fr)
POLYTHÉRAPIE COMPRENANT UN VACCIN À BASE DE NÉOANTIGÈNES

Publication
EP 3082853 A2 20161026 (EN)

Application
EP 14830923 A 20141219

Priority

- US 201361919576 P 20131220
- US 201461976274 P 20140407
- US 2014071707 W 20141219

Abstract (en)
[origin: WO2015095811A2] The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of iieopiasia in a subject.

IPC 8 full level
A61K 39/00 (2006.01); **A61K 39/395** (2006.01); **C07K 16/28** (2006.01)

CPC (source: CN EP IL KR US)
A61K 39/0011 (2013.01 - CN EP IL KR US); **A61K 39/3955** (2013.01 - IL US); **A61K 39/39558** (2013.01 - CN EP IL KR US); **A61K 45/06** (2013.01 - IL KR US); **A61P 35/00** (2018.01 - EP IL KR); **A61P 35/02** (2018.01 - EP IL); **A61P 35/04** (2018.01 - EP IL KR); **C07K 16/2803** (2013.01 - IL KR US); **C07K 16/2818** (2013.01 - EP IL KR US); **A61K 2039/505** (2013.01 - EP IL KR US); **A61K 2039/507** (2013.01 - EP IL KR US); **A61K 2039/545** (2013.01 - CN EP IL KR US); **A61K 2039/55561** (2013.01 - CN EP IL KR US); **A61K 2039/70** (2013.01 - CN EP IL KR US); **A61K 2300/00** (2013.01 - IL KR)

C-Set (source: CN EP IL KR US)
CN EP US
1. **A61K 39/0011 + A61K 2300/00**
2. **A61K 39/39558 + A61K 2300/00**
IL KR
A61K 39/0011 + A61K 2300/00

Citation (examination)

- WO 2006121168 A1 20061116 - ONO PHARMACEUTICAL CO [JP], et al
- OTT PATRICK A ET AL: "An immunogenic personal neoantigen vaccine for patients with melanoma", NATURE, SPRINGER NATURE PUBLISHING AG, LONDON, vol. 547, no. 7662, 13 July 2017 (2017-07-13), pages 217, XP002785348, ISSN: 1476-4687
- "Neon Therapeutics Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers", 15 July 2019 (2019-07-15), Retrieved from the Internet <URL:https://www.globenewswire.com/news-release/2019/07/15/1882432/0/en/Neon-Therapeutics-Personal-Neoantigen-Vaccine-Study-Demonstrates-Prolonged-Progression-Free-Survival-in-Advanced-or-Metastatic-Melanoma-Non-Small-Cell-Lung-and-Bladder-Cancers.html> [retrieved on 20200204]

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2015095811 A2 20150625; WO 2015095811 A3 20151022; WO 2015095811 A8 20160707; AU 2014368898 A1 20160728; AU 2014368898 B2 20200611; AU 2020230277 A1 20201001; AU 2020230277 B2 20240321; BR 112016014410 A2 20180220; CA 2934073 A1 20150625; CN 106456724 A 20170222; EP 3082853 A2 20161026; IL 246268 A0 20160731; IL 246268 B 20210325; IL 280908 A 20210429; IL 280908 B 20220101; IL 288618 A 20220201; IL 288618 B1 20230401; IL 288618 B2 20230801; JP 2017502029 A 20170119; JP 2020189866 A 20201126; JP 2023071936 A 20230523; JP 7060324 B2 20220426; JP 7244462 B2 20230322; KR 20160101073 A 20160824; KR 20230076867 A 20230531; NZ 721908 A 20221223; US 11452768 B2 20220927; US 2016339090 A1 20161124; US 2023190896 A1 20230622

DOCDB simple family (application)
US 2014071707 W 20141219; AU 2014368898 A 20141219; AU 2020230277 A 20200909; BR 112016014410 A 20141219; CA 2934073 A 20141219; CN 201480075117 A 20141219; EP 14830923 A 20141219; IL 24626816 A 20160616; IL 28090821 A 20210216; IL 28861821 A 20211202; JP 2016541368 A 20141219; JP 2020135858 A 20200811; JP 2023035401 A 20230308; KR 20167019282 A 20141219; KR 20237016815 A 20141219; NZ 72190814 A 20141219; US 201415105961 A 20141219; US 202217877195 A 20220729